The U.S. Court of Appeals for the D.C. Circuit on September 9 rejected a bid to freeze the Justice Department's order rescheduling parts of marijuana to Schedule III while opponents fight the policy in court. The panel said petitioners "have not satisfied the stringent requirements for a stay pending court review." The ruling does not decide whether the rescheduling order was lawful. It means the April policy stays in effect while the consolidated challenges move forward.
The D.C. Circuit denied a stay of the April 28 rescheduling order on September 9. Schedule III treatment for marijuana covered by a state medical license or an FDA-approved drug product remains in effect. The underlying petitions challenging the order have not been decided.
What Happened
In April, the Department of Justice issued a final order moving two narrow categories of marijuana from Schedule I to Schedule III under the Controlled Substances Act: marijuana covered by a state-issued medical marijuana license, and marijuana contained in an FDA-approved drug product. Recreational marijuana, and any marijuana outside those two categories, stayed in Schedule I.
Several states, including Nebraska, Indiana and Louisiana, along with Smart Approaches to Marijuana and a coalition led by MMJ International Holdings, filed petitions in the D.C. Circuit challenging the order. They asked the court to pause the rule while their case was heard. On September 9, the panel declined, finding the challengers had not cleared the high bar required for a stay pending appeal: a likelihood of success on the merits, irreparable harm without a stay, and the balance of harms and public interest favoring a pause.
Why It Matters
A stay would have frozen Schedule III treatment nationwide until the courts resolved the merits, which could take months or longer. Denying it means the current framework holds for now: state-licensed medical marijuana and FDA-approved marijuana products keep Schedule III status, while everything else remains Schedule I. That status quo carries real financial weight. Schedule III standing is the legal predicate several operators and analysts point to for relief from Internal Revenue Code Section 280E, the provision that bars standard business-expense deductions for Schedule I and II drug trafficking. Billions of dollars in anticipated tax treatment turn on whether that predicate ultimately survives the pending challenges.
The ruling also does not resolve a tension critics have raised with the order itself: state-licensed marijuana products can carry Schedule III status without the product-specific evidence of consistent chemistry, standardized dosing, manufacturing quality, safety and efficacy that the FDA normally requires before approving a Schedule III drug. That argument remains part of the pending case, not something the September 9 order addressed.
What the Ruling Does Not Decide
The D.C. Circuit's order is procedural. It does not rule on whether DOJ had the legal authority to reschedule marijuana this way, whether the agency followed proper rulemaking procedure, or whether the April order should ultimately be vacated. Those questions remain live in the consolidated petitions. A decision on the merits could still overturn the rescheduling order later, which is part of why the court's "stringent requirements" standard for a stay is deliberately hard to meet — it is meant for genuinely urgent, likely-to-succeed challenges, not every pending dispute.
It also does not change anything for marijuana outside the two rescheduled categories. Adult-use, non-medical marijuana remains Schedule I everywhere in the country, regardless of state legalization status.
What Happens Next
The consolidated challenges continue in the D.C. Circuit on their normal briefing schedule. Readers should watch for a merits ruling from the panel, not another procedural order, before treating rescheduling as settled either way. Separately, the DEA's own administrative rulemaking proceeding on broader rescheduling of all marijuana — the docket behind this summer's 11-day hearing — remains pending and unrelated to this specific stay decision.
What This Means for Texas
Nothing about the September 9 order changes Texas law. Texas has no state medical marijuana license program that mirrors the licensing structure referenced in the DOJ order; the state's Compassionate Use Program operates under its own separate framework. See our explainer on what federal rescheduling actually means for Texas patients for the distinction between a federal schedule change and state legalization, and our Schedule III explainer for the tax and research implications still working through the courts.
The Bottom Line
The D.C. Circuit kept the Schedule III order in place by declining to freeze it, not by ruling it lawful. The practical effect for now: state-licensed and FDA-approved marijuana keeps its current Schedule III status while litigation continues, and the case's ultimate outcome, including the 280E tax question many operators are watching, remains undecided.